Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center.
Current accepted prognostic indicators in ovarian cancer include performance status, surgical (FIGO) staging, and residual disease after operation. Here we present data from a prospective analysis of patients with ovarian cancer treated at the Christie Hospital. We confirm the independent prognostic effects of FIGO staging, performance status, and residual disease in our group of patients and furthermore show that CA125 levels at presentation to the oncology service are of independent prognostic significance (P= 0.02). We present survival data and show that the 3-year, cancer-specific survival for stage I disease is 90%. We postulate that this good survival may in part be due to the use of computed tomography scanning at presentation to allow accurate staging. Further clinical trials are needed to test whether combinations of surgical, histologic, biochemical, and radiologic parameters can be used to identify a population with such a good prognosis that adjuvant therapy is not required.
Board
R E
RE
Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom. ruth.board@christie-tr.nwest.nhs.uk
Bruijns
C T P H
CT
Pronk
A E
AE
Ryder
W D J
WD
Wilkinson
P M
PM
Welch
R
R
Shanks
J H
JH
Connolly
G
G
Slade
R J
RJ
Reynolds
K
K
Kitchener
H C
HC
Jayson
G C
GC
D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis / Q000401:mortality*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018394:CA-125 Antigen / Q000097:blood; D002173:Cancer Care Facilities / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis / Q000401:mortality*; D011379:Prognosis; D011446:Prospective Studies; D012720:Severity of Illness Index; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed; D006113:United Kingdom / Q000453:epidemiology
D018394:CA-125 Antigen